- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05727618
The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery
The Effect of Pituitrin on Postoperative Outcomes in Patients With Pulmonary Hypertension Undergoing Cardiac Surgery: a Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiac surgery is the most important treatment for serious coronary heart disease, valvular heart disease, congenital heart disease and other heart diseases. Its postoperative mortality and serious complications have also been widely concerned, especially in patients with pulmonary hypertension. The persistent pulmonary hypertension and systemic vascular paralysis during the perioperative period are the main causes of early postoperative death and serious complications such as organ failure.Catecholamine vasoactive drugs commonly used in cardiac surgery may aggravate the condition of pulmonary hypertension, while the use of drugs to reduce pulmonary hypertension, such as nitric oxide, prostaglandins and phosphodiesterase inhibitors, may worsen the state of systemic vascular paralysis.
Vasopressin and oxytocin are two effective components in pituitrin, and vasopressin is the main component that exerts strong vasoconstrictive effect.Vasopressin binds to receptors distributed in vascular smooth muscle, pituitary and kidney, and exerts its effects by regulating adenosine triphosphate sensitive K+ channel function, nitric oxide production and enhancing vascular response to catecholamine.In addition, oxytocin can also bind to the receptors distributed in the heart and vascular endothelium, and play a role by releasing atrial natriuretic peptide and nitric oxide.Therefore, pituitrin can not only constrict systemic circulation vessels and increase systemic circulation pressure, reduce pulmonary artery pressure and pulmonary vascular resistance, but also protect the heart and kidney.
Therefore, this study intends to explore whether pituitrin has an impact on the prognosis of patients with pulmonary hypertension after cardiac surgery, so as to provide reference for its clinical application.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Quan Li, doctor
- Phone Number: 13964017257
- Email: liquann@163.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥18 years and ≤80 years;
- scheduled for elective cardiopulmonary bypass heart surgery (adult congenital heart disease surgery, coronary artery bypass grafting, valve replacement, valvuloplasty, heart transplantation and aortic surgery);
- Patients who had pulmonary hypertension (Mean pulmonary artery pressure at rest ≥ 25mmhg or pulmonary artery systolic pressure (PASP) ≥ 40mmhg as shown by echocardiography);
- sign informed consent.
Exclusion Criteria:
- use pituitrin or vasopressin before operation;
- Patients who had acute coronary syndrome;
- preoperative use of left ventricular assist devices other than intra aortic balloon - pump (IABP);
- Patients who had liver, thyroid and adrenal diseases, severe lung diseases, diabetes;
- Patients who had preoperative renal insufficiency (The increase of serum creatinine (SCR) within 48 h ≥ 0.3mg/dl (or ≥ 26.5 μ mol/L); Or it is known or speculated that the increase of SCR in the past 7 days is more than 1.5 times of the basic value; Or 0.5ml/kg urine volume per hour for 6H);
- Patients who had severe carotid artery stenosis, preoperative stroke, mental disorder and other difficult to communicate and cooperate;
- Patients who had peripheral vascular disease, allergy to vasopressin or pituitrin, severe hyponatremia (na+ < 130 mmol/l), acute mesenteric ischemia, pregnancy, malignant tumors, required ECMO and underwent emergency surgery or reoperation;
- Patients who had participated in other clinical studies in recent 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: pituitrin group
The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
|
The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
|
PLACEBO_COMPARATOR: normal saline group
Intravenous infusion of normal saline at the same dose and speed
|
Intravenous infusion of normal saline at the same dose and speed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
a composite endpoint of mortality or severe postoperative complications
Time Frame: Within 30 days after cardiac surgery
|
severe complications after cardiac surgery, including stroke, requirement of mechanical ventilation for longer than 48h, deep sternal wound infection, reoperation, or acute renal failure
|
Within 30 days after cardiac surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of postoperative infection
Time Frame: Within 30 days after cardiac surgery
|
The patient appears infection after surgery.
|
Within 30 days after cardiac surgery
|
septic shock
Time Frame: Within 30 days after cardiac surgery
|
Septic shock was defined as the septic syndrome with shock caused by microorganisms and their toxins.
|
Within 30 days after cardiac surgery
|
duration of mechanical ventilation
Time Frame: Time from the beginning of mechanical ventilation to the end of mechanical ventilation up to 30 days after cardiac surgery.
|
Total duration of mechanical ventilation during or after surgery.
|
Time from the beginning of mechanical ventilation to the end of mechanical ventilation up to 30 days after cardiac surgery.
|
postoperative pulmonary complications
Time Frame: Within 30 days after cardiac surgery
|
This is a composite endpoint indicator, includs atelectasis, pleural effusion, diaphragmatic dysfunction, prolonged mechanical ventilation, pneumonia, pneumothorax, acute respiratory distress syndrome, etc.The occurrence of any of the above pulmonary complications is considered as a positive outcome.
|
Within 30 days after cardiac surgery
|
time to achieve hemodynamic stability
Time Frame: Within 30 days after cardiac surgery
|
From hemodynamic change to hemodynamic stability.
|
Within 30 days after cardiac surgery
|
use of dobutamine or other vasoactive drugs
Time Frame: Within 30 days after cardiac surgery
|
The patients use dobutamine or other vasoactive drugs.
|
Within 30 days after cardiac surgery
|
incidence of digital ischemia
Time Frame: Within 30 days after cardiac surgery
|
Digital ischemia is a symptom caused by insufficient blood supply to the fingers.
|
Within 30 days after cardiac surgery
|
acute mesenteric ischemia
Time Frame: Within 30 days after cardiac surgery
|
Acute mesenteric ischemia includes arterial and venous thrombosis, thrombosis, and vasoconstriction secondary to low blood flow.
Arterial lesions mainly included superior mesenteric artery embolism, superior mesenteric artery thrombosis and non occlusive mesenteric ischemia.
The main venous lesions were mesenteric venous thrombosis.
|
Within 30 days after cardiac surgery
|
gastrointestinal complications
Time Frame: Within 30 days after cardiac surgery
|
Including dyspepsia, abdominal distension, constipation, postoperative stress ulcer, gastrointestinal bleeding, etc.
|
Within 30 days after cardiac surgery
|
incidence of acute myocardial infarction
Time Frame: Within 30 days after cardiac surgery
|
Acute myocardial infarction is myocardial necrosis caused by acute and persistent ischemia and hypoxia of coronary artery.
|
Within 30 days after cardiac surgery
|
new onset tachyarrhythmia
Time Frame: Within 30 days after cardiac surgery
|
Tachyarrhythmia includes premature beat, tachycardia, atrial fibrillation and ventricular fibrillation, etc.
|
Within 30 days after cardiac surgery
|
water poisoning
Time Frame: Within 30 days after cardiac surgery
|
Water poisoning refers to that when the total amount of water ingested by the body greatly exceeds the amount of water discharged, so that water is retained in the body, resulting in the decrease of plasma osmotic pressure and the increase of circulating blood volume.
|
Within 30 days after cardiac surgery
|
vasodilative shock
Time Frame: Within 30 days after cardiac surgery
|
Vasodilative shock is caused by vasodilation, increased vascular bed volume and relatively insufficient intravascular blood volume, including septic shock, anaphylactic shock and neurogenic shock.
|
Within 30 days after cardiac surgery
|
incidence of pulmonary embolism
Time Frame: Within 30 days after cardiac surgery
|
Pulmonary embolismwas defined as clinical pathophysiological syndrome of pulmonary circulatory dysfunction caused by pulmonary artery and its branches blocked by various emboli falling off of systemic circulation.
|
Within 30 days after cardiac surgery
|
low cardiac output syndrome
Time Frame: Within 30 days after cardiac surgery
|
Low cardiac output syndrome refers to the complex pathophysiological changes of insufficient perfusion of multiple organs and tissue hypoxia due to the decrease of cardiac output.
|
Within 30 days after cardiac surgery
|
acute respiratory distress syndrome
Time Frame: Within 30 days after cardiac surgery
|
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by refractory hypoxemia, which is caused by intrapulmonary and / or extrapulmonary causes.
|
Within 30 days after cardiac surgery
|
delirium
Time Frame: Within 30 days after cardiac surgery
|
Delirium refers to a group of syndromes, also known as acute brain syndrome.
It is manifested as consciousness disorder, disorganized behavior, no purpose and unable to concentrate.
|
Within 30 days after cardiac surgery
|
need for renal replacement therapy (RRT)
Time Frame: Within 30 days after cardiac surgery
|
Replacement therapy usually includes hemodialysis, peritoneal dialysis and kidney transplantation.
|
Within 30 days after cardiac surgery
|
need for hemodialysis
Time Frame: Within 30 days after cardiac surgery
|
Hemodialysis (hd) is one of the renal replacement therapies for patients with acute and chronic renal failure.
|
Within 30 days after cardiac surgery
|
incidence of readmission to ICU
Time Frame: Within 30 days after cardiac surgery
|
The patients re-enters ICU.
|
Within 30 days after cardiac surgery
|
length of ICU stay
Time Frame: Within 30 days after cardiac surgery
|
From the day of surgery to the time the patient leaves the ICU.
|
Within 30 days after cardiac surgery
|
length of stay
Time Frame: Within 30 days after cardiac surgery
|
From the day of surgery to the time the patient leaves the hospital.
|
Within 30 days after cardiac surgery
|
levels of serum antidiuretic hormone in patients
Time Frame: at entering the operating room(T1), 4 hour(T2), 12 hour(T3) and 24 hour(T4) postoperatively
|
T1-T4 were defined as entering the operating room, 4, 12 and 24 hour postoperatively, respectively.
|
at entering the operating room(T1), 4 hour(T2), 12 hour(T3) and 24 hour(T4) postoperatively
|
levels of copeptin in patients
Time Frame: at entering the operating room(T1), 4 hour(T2), 12 hour(T3) and 24 hour(T4) postoperatively
|
T1-T4 were defined as entering the operating room, 4, 12 and 24 hour postoperatively, respectively.
|
at entering the operating room(T1), 4 hour(T2), 12 hour(T3) and 24 hour(T4) postoperatively
|
secondary endotracheal intubation
Time Frame: Within 30 days after cardiac surgery
|
Secondary endotracheal intubation refers to the second endotracheal intubation after the patient's postoperative endotracheal intubation is removed.
|
Within 30 days after cardiac surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Quan Li, doctor, Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LM-KLC-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Pulmonary
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on Pituitrin
-
Beijing Anzhen HospitalUnknownPostoperative Vasoplegic SyndromeChina